PALO ALTO, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on September 06, 2023, the compensation committee of BridgeBio’s board of directors granted twenty-four new employees restricted stock units…Read More
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635c4
